Providence Hospital 1st in Michigan to Offer New Heart Failure Monitoring Solution
SOUTHFIELD, Mich., Feb. 10, 2015 /PRNewswire-USNewswire/ -- Providence Hospital is the first in the state to implant a new miniaturized, wireless monitoring sensor to manage heart failure. The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.
The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery during a non-surgical procedure (similar to angioplasty) to directly measure PA pressure. Increased pulmonary artery pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure.
The new system allows patients to transmit daily sensor readings from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization. The external measurement system wirelessly tracks frequency and uses it to determine the pressure in the pulmonary artery. At home, patients use a portable electronic unit and a special pillow containing an antenna to take daily sensor readings. This is a simple process that takes only a few minutes. The patient's electronic unit is turned on and the patient lies on the pillow. The electronic unit uses audible signals telling the patient to press the button to initiate a reading. The pressure readings are then wirelessly transmitted to a secure website.
"This innovative system enhances our ability to monitor and ultimately improve outcomes for heart failure patients without the need for additional clinic visits," according to Shukri David, M.D. chief of cardiology at Providence. "We can detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized."
Heart failure occurs when the heart is unable to pump enough blood to meet the body's demands. According to the Centers for Disease Control and Prevention, more than 5.1 million Americans have heart failure, with 670,000 new cases diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death.
Data from a clinical trial showed that the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. The CHAMPION trial studied the effectiveness of the CardioMEMS HF System in New York Heart Association (NYHA) Functional Classification System class III heart failure patients who had been hospitalized for heart failure in the previous 12 months. Results of the trial demonstrated a statistically significant 28 percent reduction in the rate of heart failure hospitalizations at six months, and 37 percent reduction in heart failure hospitalizations during an average follow-up duration of 15 months. Roughly 1.4 million patients in the U.S. have NYHA Class III heart failure, and historically these patients account for nearly half of all heart failure hospitalizations. According to the American Heart Association, the estimated direct and indirect cost of heart failure in the U.S. for 2012 was $31 billion and that number is expected to more than double by 2030.
Providence Hospital is a member of the St. John Providence Health System Heart & Vascular Care Network, a leading provider of heart care in Michigan. For 12 years, Providence has been ranked as one of the top hospitals in the United States for heart care, according to an independent national study conducted by Truven Health Analytics. Providence is also recognized as Blue Distinction Centers for Cardiac Care by Blue Cross Blue Shield of Michigan.
SOURCE St. John Providence Health System
Related Links
http://www.stjohnprovidence.org
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article